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Summary
 
Apoptosis is critical to homeostasis of multicellular organisms. In immune privileged sites such as
the eye, CD95 ligand (FasL)-induced apoptosis controls dangerous inflammatory reactions that
can cause blindness. Recently, we demonstrated that apoptotic cell death of inflammatory cells
was a prerequisite for the induction of immune deviation after antigen presentation in the eye. In
this report, we examine the mechanism by which this takes place. Our results show that Fas-
mediated apoptosis of lymphoid cells leads to rapid production of interleukin (IL)-10 in these
cells. The apoptotic cells containing IL-10 are responsible for the activation of immune deviation
through interaction with antigen-presenting cells (APC). In support of this, we found that apop-
totic cells from IL-10
 
1
 
/
 
1
 
 animals fed to APC in vitro promote Th2 cell differentiation, whereas
apoptotic IL-10
 
2
 
/
 
2
 
 cells, as well as nonapoptotic cells, favor Th1 induction. Thus, apoptotic cell
death and tolerance are linked through the production of an antiinflammatory cytokine to pre-
vent dangerous and unwanted immune responses that might compromise organ integrity.
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ike cell proliferation, apoptosis is a continuous physio-
logical process associated with embryonic development,
metamorphosis, immune system maturation, and cell turn-
over (1). This type of cell death differs from necrotic death in
that apoptosis is a highly regulated process induced by a spe-
cific stimulus, whereas necrosis results from the failure to
control cellular homeostasis after injury. Apoptosis is an in-
dispensable part of adaptive immunity since the immune sys-
tem must deal with pathogens, as well as its own potentially
damaging cells, to prevent the formation of self-reactive re-
sponses and autoimmunity (2). One hallmark of apoptotic
death is that dead cells are recognized, phagocytized (3), and
removed to minimize inflammatory or immune reactions that
could result from the release of cellular components. How-
ever, it has been noted that apoptosis can actually prevent or
inhibit inflammatory responses, suggesting that immune
regulatory processes might result from its induction. Indeed,
the well-documented antiinflammatory effects of UV irradia-
tion are an excellent example, in which exposure of skin to
UV radiation of wavelength 280–320 nm (UVB)
 
1
 
 leads to
the direct inhibition of cell mediated immunity through the
induction of inhibitory cytokines (4). Similarly, recent studies
have shown that apoptosis of lymphoid cells in an immune
privileged site leads to the induction of immune deviation (5).
In immunology there is considerable interest in a cell
surface receptor protein that induces apoptotic death when
ligated by specific antibody or its natural ligand. This pro-
tein, Fas (APO-1, CD95), is related to members of the
TNF receptor family with broad distribution on both lym-
phoid and nonlymphoid cells. The natural ligand for Fas
(CD95 ligand, Fas ligand, FasL) is a member of the TNF
family of cytokines that has been found in numerous sites
throughout the body (6). Fas–FasL interactions have been
implicated as the mechanism behind clonal deletion after in
vivo exposure to superantigen and peptide (7), controlling
T cell expansion during immune responses (6), and killing
by cytotoxic T cells (8). It has also been shown that FasL
plays an important role in tumor biology, since a growing
number of tumors have been found to express functional
FasL as a protective mechanism against the Fas
 
1
 
 cells of the
immune system (9, 10).
Fas–FasL interactions are also important in the mainte-
nance of immune privilege in organs such as the eye (11),
the placenta (12), and the testis (13). Inflammatory reac-
tions are inhibited in immune privileged sites since even
minor episodes can threaten organ integrity and function.
In the eye constitutive FasL expression controls the prolifera-
 
1
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tion of Fas
 
1
 
 lymphoid cells that enter this organ in response
to viral infection (11), and it is a significant factor in the re-
markable success of corneal transplants (14). FasL-induced
cell death of lymphoid cells is also critical to the induction of
immune deviation to antigens placed in the eye (5). This
form of immune deviation requires apoptotic cell death of
Fas
 
1
 
 lymphoid cells induced by FasL
 
1
 
 ocular cells. Interest-
ingly, it is death by apoptosis that is the critical factor, rather
than cell death restricted to the Fas–FasL pathway.
In current paradigms, immune deviation is the preferen-
tial activation of one Th cell subset over another, and in
the case of the eye a Th2-type response is typically in-
duced. This is manifested by a dominant antibody response,
a diminished delayed-type hypersensitivity (DTH) response
(15–19), and the loss of IFN-
 
g
 
 production (5). The pro-
duction of Th2 cytokines IL-4 and/or IL-10 in the spleen
has also been noted in animals with immune deviation in-
duced in this manner (20). The link between cell death and
immune deviation suggests that there may be an antiinflam-
matory component to apoptosis in the eye that is manifest
through the inhibition of systemic immune responses. Here
we examine the mechanisms linking apoptosis and immune
regulation using a combination of in vivo and in vitro meth-
ods. Our results show that apoptosis of immune effector cells
can redirect the final outcome of an immune response
through the production of an antiinflammatory cytokine that
regulates immunity through interaction with APC.
 
Materials and Methods
 
Mice
 
C57BL/6 (B6) and BALB/c were purchased from the Na-
tional Cancer Institute. C57BL/6-
 
lpr
 
 (B6-
 
lpr
 
) mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). B6-bcl-x
 
L
 
transgenic mice (21) were provided by Dr. Stan Korsmeyer
(Washington University). DO11.10 transgenic mice (22, 23)
were provided by Dr. Ken Murphy (Washington University).
B6-IL-10
 
2
 
/
 
2
 
 and B6-IL-4
 
2
 
/
 
2
 
 mice were provided by Dr. Osami
Kanagawa (Washington University). In all in vivo experiments,
groups consisted of five or more animals. Experiments were re-
peated at least three times with similar results before they were
reported.
 
Reagents
 
2,4,6-trinitro-1-chlorobenzene (TNCB) was purchased from
Eastern Chemical Co. (Smithtown, NY). 2,4,6 trinitrobenzene
sulfonic acid (TNBS) was purchased from Sigma Chemical Co.
(St. Louis, MO). Recombinant murine IL-10, IL-4, and IFN-
 
g
 
, as
well as the rat anti–mouse mAbs to IL-10 (SXC-1 and JES5.2A5)
were purchased from Genzyme Inc. (Cambridge, MA).
Medium for all in vitro cultures was DME media (Sigma
Chemical Co., St. Louis, MO) supplemented with 10% FCS,
 
L
 
-glutamine, sodium pyruvate, penicillin/streptomycin/fungi-
zone, Hepes, and 2 
 
3
 
 10
 
2
 
5
 
 M 2-mercaptoethanol.
 
Isolation of T Cells
 
T cells were isolated from spleen cell suspensions as previously
described (15, 16). In brief, 5-ml econocolumns (Bio-Rad Labo-
ratories, Richmond, CA) were filled with glass beads (mean di-
ameter 200 
 
m
 
m) coated with normal mouse Ig. The columns
were washed 3
 
3
 
 with HBSS, followed by the addition of a 1/6
dilution of rabbit anti–mouse Ig. After a 1-h incubation, the col-
umn was washed 3
 
3
 
 with HBSS. Spleen cells (10
 
8
 
 cells/2.5-ml
beads) were added to the column with a flow rate of one drop per
6–10 s. Cells were collected as they emerged from the column.
Yields were typically 25–30% of the applied cells that consisted of
95–98% CD3
 
1
 
 cells.
 
TNP Coupling of Cells
 
RBC-free single-cell suspensions of purified T cells were cou-
pled with TNP as previously described (15, 16). In brief, 10
 
8
 
 cells
were incubated in 0.5 ml HBSS and 0.5 ml 10 mM TNBS for
7–10 min at room temperature. After incubation, cells were
washed 3
 
3
 
 with HBSS before use.
 
Induction of Immune Deviation
 
Immune deviation was induced as described (15, 16, 24). In
brief, TNP-coupled T cells (5 
 
3
 
 10
 
5
 
) were injected into the ante-
rior chamber (AC) in 0.005-ml vol using a 0.25-ml Hamilton
Microliter syringe (Hamilton Co., Reno, NV) fitted with a 33-
gauge needle. Mice were anesthetized with Metofane (methoxy-
flurane) and injections were done under a dissecting microscope.
In some experiments, irradiated TNP-T cells were used for injec-
tion. These cells were used within 1 h of treatment with 3,000 R
 
g
 
-irradiation. Mice were immunized 48 h after AC injection
with 0.050 ml of 1% TNCB in acetone/olive oil (3:1) applied to
shaved abdominal skin. 5 d later mice were challenged with 0.033
ml 10 mM TNBS in PBS in the right footpad and 0.033 ml PBS
in the left footpad. Measurements were made 24 h later using an
engineer’s micrometer. Values are expressed in 
 
m
 
m (
 
6
 
 SE) and
represent the difference between the right footpad (antigen chal-
lenge) and the left footpad (PBS challenge). Background values
represent the difference between the challenged and unchal-
lenged foot in unimmunized mice.
 
Generation of Peritoneal Exudate Cells
 
Peritoneal exudate cells (PEC) used for transfer to naive mice
after incubation with apoptotic cells were harvested by lavage
from adult mice injected intraperitoneally 3 d earlier with 0.1 ml
IFA (Sigma Chemical Co.). PEC used in the DO11.10 cultures
were prepared by injecting 1.0 ml i.p. of freshly prepared ConA
in saline (60 
 
m
 
g/ml; Sigma Chemical Co.), followed 4 d later
with 0.5 ml of 3% proteose peptone (Difco, Detroit, MI). Cells
were harvested 3 d later by peritoneal lavage. By FACS
 
Ò
 
 analysis
the adherent cells were MHC class II
 
1
 
 (66%), Mac-1
 
1
 
 (88%), F4/
80
 
1
 
 (66%), B7-1
 
1
 
 (56%), B7-2
 
1
 
 (73%), LFA-1
 
1
 
 (95%), and
B220
 
2
 
.
 
Adoptive Transfer of Adherent Cells
 
After harvest from the peritoneum of IFA-treated mice, 5 
 
3
 
10
 
6
 
 cells in 1 ml of DME/10% FCS were placed in the wells of a
24-well plate and incubated for 2 h at 37
 
8
 
C in a 5% CO
 
2
 
 incuba-
tor. Wells were then washed 3
 
3
 
 with HBSS and 1 
 
3
 
 10
 
6
 
 spleen
cells (irradiated or untreated) were added per well. After two ad-
ditional hours of incubation at 37
 
8
 
C, wells were washed 3
 
3
 
 with
HBSS and the plates placed at 4
 
8
 
C for 30 min. Cells were dis-
lodged by vigorous pipetting, washed again in HBSS, counted,
and 1 
 
3
 
 10
 
4
 
 viable cells were transferred to naive mice. Recipient
mice were immunized with TNCB to determine if immune de-
viation was established as described above. 
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DO11.10 Cultures
 
PEC (1.5 
 
3
 
 10
 
6
 
 in 2 ml DME/10% FCS) were placed in
wells of a 24-well plate. After 2 h incubation at 37
 
8
 
C, nonadher-
ent cells were removed by washing with HBSS. OVA protein
(100 
 
m
 
g/ml) along with irradiated (3,000 R) or untreated TNP-T
cells (1 
 
3
 
 10
 
6
 
) were added. Recombinant murine IL-10 (40 ng/
ml) was added to some wells as a control. After 2–4 h incubation
at 37
 
8
 
C, the medium was removed and PEC were extensively
washed to remove any nonassociated cells. OVA (100 
 
m
 
g/ml) and
3 
 
3
 
 10
 
5
 
 purified DO11.10 T cells were then added to the well
and the cultures were maintained for 5 d at 37
 
8
 
C in a 5% CO
 
2
 
 at-
mosphere. Live cells were then collected, washed with HBSS,
and restimulated with 0.3 
 
m
 
M OVA
 
323–339
 
 peptide plus fresh irradi-
ated syngeneic splenocytes as APC. 48 h later supernatants were
collected and the amount of IL-4 and IFN-
 
g
 
 was determined as
described below. Cytokine profiles of the resulting cell populations
are displayed graphically as described (22, 23), where the amount of
IL-4 (y axis) is plotted versus the amount of IFN-
 
g
 
 (x axis).
 
Cytokine Production in Spleen of Mice with
Immune Deviation
 
4 d after immunization of mice with TNCB, the splenocytes
were collected and coupled with TNP as described above. 10
 
6
 
cells per well in a 24-well plate were cultured in DME and 10%
FCS and supernatants were collected 48 h later. Cytokine content
was measured as described below.
 
IL-10 Production In Vitro
 
Splenocytes from mice were harvested and RBC-free single-
cell suspensions prepared. Cells were exposed to 3,000 R irradia-
tion and 1 
 
3 
 
10
 
7
 
 cells/2 ml were cultured in DME and 10% FCS
24 h. Supernatants were then collected. Splenocytes from B6,
B6-
 
lpr
 
, and bcl-x
 
L
 
 transgenic mice were exposed to FasL by in-
cubating 1 
 
3 
 
10
 
7
 
 spleen cells with 1.5 
 
3 
 
10
 
6
 
 murine FasL-
expressing L cells (obtained from Dr. John Russell, Washington
University) in DME and 10% FCS. Supernatants were harvested
24 h later. T hybridoma A1.1 (28; 10
 
6
 
/well in a 24-well plate)
was activated with 10 ng/ml PMA (Sigma Chemical Co.) and
500 ng/ml Ionomycin (Sigma Chemical Co.) overnight and su-
pernatants were collected. Where indicated, 10 
 
m
 
g/ml Fas-Fc
chimeric protein (obtained from Dr. Douglas Green, La Jolla Insti-
tute; reference 28) was included in the culture to block apoptosis.
All supernatants generated were assayed for IL-10 by ELISA as
described below.
 
Detection of Cytokines
 
IFN-
 
g
 
.
 
Serial dilution of recombinant murine IFN-
 
g
 
 or su-
pernatant was added to wells of 4 
 
3
 
 10
 
3
 
 WEHI-279 cells in
DME and 10% FCS in a 96-well plate. Cultures were incubated
for 40 h at 37
 
8
 
C in 5% CO
 
2
 
, pulsed 8 h with 1 
 
m
 
Ci [
 
3
 
H]TdR,
and harvested for scintillation counting. Growth inhibition of
WEHI-279 reflected the amount of IFN-
 
g
 
 (U/ml) that was de-
termined by comparison to the standard curve constructed from
values obtained with recombinant IFN-
 
g
 
.
 
IL-4.
 
Serial dilution of recombinant murine IL-4 or superna-
tant was added to wells of 2 
 
3
 
 10
 
3
 
 6I4 cells in DME and 10%
FCS. Cultures were incubated for 32 h at 37
 
8
 
C in 5% CO
 
2
 
,
pulsed 16 h with 1 
 
m
 
Ci [
 
3
 
H]TdR, and harvested for scintillation
counting. Growth of 6I4 reflected the amount of IL-4 (U/ml)
which was determined by comparison to a known standard (re-
combinant murine IL-4).
 
IL-10.
 
IL-10 was quantitated using a sandwich ELISA devel-
oped with two anti–IL-10 mAbs as described (25). ELISA plates
(96-well, Nunc Polysorb Immuno plates; Roskilde,
 
 
 
Denmark)
were coated with purified JES5.2A5 mAb (2 
 
m
 
g/ml) diluted in
coating buffer (0.1 M NaHCO
 
3
 
 and 0.1 M Na
 
2CO3). After over-
night incubation at 48C, wells were blocked with 1% BSA in PBS
for 2 h at room temperature. Plates were then washed 33 with
PBS containing 0.1% Tween-20 (PBS/Tween) and the recombi-
nant murine IL-10 standard or test samples were added (100 ml/
well). Standard and unknowns were diluted in PBS/Tween con-
taining 1% BSA. Plates were incubated overnight at 48C, wells
were washed 43 with PBS/Tween, and 100 ml/well of biotiny-
lated mAb SXC-1 (1 mg/ml) was added for 45 min at room tem-
perature. Wells were washed at least six times, followed by the
addition of 100 ml of 1:500 avidin-alkaline phosphatase (Sigma
Chemical Co.) for 30 min at room temperature. Wells were
washed at least eight times with PBS/Tween and 100 ml of p-nitro-
phenyl phosphate (Zymed Labs, South San Francisco, CA) was
added. Upon color development, the plate was analyzed on an
ELISA plate reader at 405 nm OD. The ELISA did not react with
IL-2, IL-4, TNF-a, IL-1a, or IFN-g.
Statistical Analysis. Significant differences between groups
were evaluated using a two-tailed Student’s t test (P , 0.01).
Results
Apoptotic Cells Make IL-10. The direction of the re-
sponse elicited by AC injection of antigen is established
very early (within the first two days) by apoptotic cell death
of T cells in the eye (5). Since production of IL-4 and IL-
10 can direct Th cell differentiation toward a Th2 response,
we asked whether a potent apoptotic signal delivered to Fas1
cells could induce the production of these cytokines. Al-
though we could not detect IL-4 (not shown), results in Fig.
1 A show that cells induced to undergo Fas-mediated apop-
tosis produce a significant amount of IL-10 protein. Super-
natants from normal spleen cells had undetectable quantities
of IL-10, but spleen cells exposed to FasL (FasL1 L cells) had
significant levels. Exposure of B6-lpr splenocytes to FasL in-
duced low levels of IL-10 demonstrating that the induction
was via a Fas–FasL interaction. Interestingly, irradiation of
B6 or B6-lpr spleen cells also leads to IL-10 production sug-
gesting that IL-10 production may be linked to the apoptosis
rather than solely to the Fas–FasL pathway.
To further explore the role of apoptosis in IL-10 pro-
duction, we examined spleen cells from bcl-xL transgenic
mice whose T cells overexpress bcl-xL (21). Bcl-xL has
been shown to protect cells from apoptotic cell death,
and it has recently been shown that it can block Fas–FasL-
induced cell death (5, 27). In our system, TNP-T cells
overexpressing bcl-xL did not undergo apoptosis in the eye,
nor could they activate immune deviation (5). As shown in
Fig. 1 A, bcl-xL transgenic cells did not produce IL-10
when given a potent FasL signal. This is consistent with the
idea that it is apoptotic T cells that are producing IL-10
since blocking Fas-mediated apoptosis prevents the IL-10
production.
To further examine whether T cells induced to undergo
apoptosis produce IL-10 we examined a T cell hybridoma
that undergoes Fas–FasL-mediated activation-induced cell890 Apoptosis and Inflammation
death (AICD) after exposure to PMA and ionomycin (28).
These results (Fig. 1 B) show that activation of A1.1 in-
duced significant IL-10 production that was absent when
apoptosis was prevented by the addition of the chimeric
protein Fas-Fc. We conclude from data in Fig. 1 that cells
induced to undergo apoptosis by Fas or irradiation produce
IL-10. When cell death is prevented, either by blocking the
Fas–FasL interaction, or overexpression of bcl-xL, IL-10 is
not produced. IL-10 production in our studies was not the
result of the release of preformed IL-10 for two reasons.
First, induction of apoptosis by either irradiation or Fas re-
sulted in rapid IL-10 mRNA production as detected by
RT-PCR (Fig. 1 A). Second, IL-10 protein was not de-
tected in unstimulated T cells when total cell extracts were
analyzed (Fig. 1 A) by ELISA.
Immune Deviation and IL-10. We further examined the
role of Th2 cytokine production in apoptotic lymphoid
cells using a well-established model for the induction of
immune deviation (5, 15, 16, 25, 29). We compared the
ability of normal, IL-42/2, and IL-102/2 TNP–coupled T
cells to induce immune deviation in normal B6 mice. As
shown in Fig. 2 A, TNP-T cells from B6 and IL-42/2 mice
induced immune deviation, whereas those from IL-102/2
mice did not. Fig. 2 B shows the cytokine profiles from the
spleens of these animals and verifies that immune deviation
was established. Mice receiving TNP-T cells from IL-101/1
mice produced significant IL-4 and very little IFN-g,
whereas mice receiving IL-102/2 cells had significant
IFN-g production and were indistinguishable from im-
mune animals in this respect.
Because apoptosis is required for the induction of im-
mune deviation, one possible explanation for the inability
of IL-102/2 cells to induce immune deviation was that
IL-102/2cells were incapable of undergoing apoptosis in the
eye. To address this, IL-102/2 TNP-T cells were killed by
g-irradiation before injection into the eye. This procedure
did not allow IL-102/2 TNP-T cells to induce immune de-
viation (Fig. 2 C), as was the case for TNP-coupled lpr cells
when apoptosis was induced in this manner (5). Even when
the concentration of the TNP IL-102/2 cells was increased
103 (not shown), they were incapable of stimulating im-
mune deviation. TUNEL stains 24 h after injection of
TNP-cells confirmed that IL-102/2 cells that were not ir-
radiated actually underwent apoptosis in the eye after injec-
tion into the AC (not shown).
Immune Deviation in IL-102/2 and IL-42/2 Mice. Our re-
sults suggest that IL-10 production induced by Fas-medi-
ated apoptosis was required for the induction of immune
deviation. This further emphasizes that early antiinflamma-
tory events (i.e., apoptosis and IL-10 production) in a rela-
tively small lymphoid cell population can dictate the out-
come of a systemic immune response. The question then
became whether presentation of apoptotic cells that do
produce IL-10 to animals incapable of producing IL-10
would have an effect. To test this, IL-102/2 mice were
injected in the AC with TNP-T cells from IL-101/1 or
IL-102/2 mice. IL-102/2 mice have been shown to have
heightened and uncontrolled DTH responses due to the
lack of this important antiinflammatory cytokine (30). As
shown in Fig. 3 A, normal B6 mice had a typical 24 h peak
response that returned to near background level by 72 h.
IL-102/2 mice had a heightened response that did not di-
minish by 72 h after challenge. Interestingly, treatment of
IL-102/2 mice with IL-101/1 cells resulted in inhibited
DTH that never developed during the 3-d measurement pe-
riod. Cytokine profiles (Fig. 3 B) confirmed the DTH data
by showing that IL-102/2 mice receiving IL-101/1 TNP-
cells have significantly reduced IFN-g production compared
with IL-102/2 mice and mice receiving IL-102/2 TNP-cells
in the AC. In contrast to these results, IL-42/2 mice do not
develop immune deviation when presented with TNP-T
cells from B6 mice (Fig. 3 C). Thus, immune deviation can
be established in IL-102/2 mice when apoptotic cells con-
taining IL-10 are presented in the eye. However, IL-4 is re-
quired systemically to activate immune deviation even when
IL-10 containing apoptotic cells are present in the eye.
Apoptotic Cells and Antigen Presentation. Results obtained
from our in vivo experiments suggest that IL-10 produc-
Figure 1. Apoptotic cells make
IL-10. (A) Splenocytes from B6,
B6-lpr, or B6-bcl-xL transgenic
mice were cultured alone or
with FasL1 L cells (FasL). B6 or
B6-lpr splenocytes were given
3,000 R irradiation (Xrad). After
24 h supernatants were harvested
and the amount of IL-10 deter-
mined by ELISA. (B) The T hy-
bridoma cell A1.1 was cultured
alone, or with PMA/Ionomycin
(act) for 18 h and the supernatants
collected. The chimera protein
Fas-Fc (10 mg/ml) was included
in some wells to block apoptosis.
The amount of IL-10 was deter-
mined by ELISA. These experi-
ments were repeated at least three
times with similar results.891 Gao et al.
tion in apoptotic cells is responsible for the effect of cell
death on the immune response. Even when mice are inca-
pable of producing IL-10, IL-101/1 apoptotic cells pre-
sented via the eye can establish immune deviation. We
were then interested in how these effects could be ampli-
fied from the eye to influence the systemic immune re-
sponse. One possibility is through the function of APC that
are involved very early in determining the direction of an
immune response by virtue of their cytokines (e.g., IL-12;
references 22, 23) and costimulators (e.g., B7-1, B7-2; ref-
erence 31). APC have also been shown to be involved in
immune deviation induced via the eye (19, 29). To test the
effect of apoptotic cells on antigen presentation we incu-
bated adherent PEC with TNP-T cells that were either ir-
radiated (apoptotic; reference 5) or left untreated (nonap-
optotic). 2 h later PEC were washed, dislodged from the
plate, and injected intravenously into naive recipients. Re-
sults in Fig. 4 A show that PEC given apoptotic cells in-
duced immune deviation when transferred, whereas those
fed nonapoptotic cells did not. FACSÒ analysis for Thy-1
and CD3 revealed that excess apoptotic cells were not car-
ried in the transferred population (not shown). A similar
experiment was performed in Fig. 4 B where the T cell hy-
bridoma A1.1 was activated to produce IL-10 (see Fig. 1 B)
and coupled with TNP before incubation for 2–4 h with
PEC. Adoptive transfer of these PEC intravenously to
naive recipients resulted in the induction of immune devia-
tion in recipient mice. (Note: We examined the expression
of B7-1 and B7-2 on APC exposed to apoptotic and non-
apoptotic IL-101/1 cells, as well as APC fed IL-102/2 T
cells. These studies found no significant influence on the
expression of these costimulatory molecules [not shown].)
Apoptotic Cells Can Direct Th Cell Development In Vitro. Al-
though the data in Fig. 4 suggest that apoptotic cells induce
immune deviation through processing and presentation by
APC, we sought a more direct proof that apoptotic cells
could influence T cell development. For these studies we
employed a well established in vitro system (22, 23) where
T cells from DO11.10 transgenic mice are cultured with
APC in the presence of OVA. The development of Th1 or
Figure 2. Immune deviation and IL-10. (A) Immune deviation. B6
mice were AC-injected with TNP-T cells prepared from normal B6, IL-
42/2, or IL-102/2 mice 48 h before immunization with 1% TNCB on
shaved abdominal skin. 5 d later mice were challenged with 0.033 ml 10
mM TNBS in PBS in the right footpad and 0.033 ml PBS in the left foot-
pad. Measurements (mm 6 SE) were taken 24 h later and represent the
difference between right footpad (antigen challenge) and left footpad
(PBS challenge). Background (Bkg) values represent the difference
between challenged and unchallenged sites in naive mice. (B) Cytokine
production. B6 mice were injected AC with TNP-coupled IL-101/1 or
IL-102/2 T cells 48 h before immunization with 1% TNCB on shaved
abdominal skin. 4 d later spleens were harvested, single-cell suspensions
prepared, and cells were coupled with TNP. Cells were then cultured in
DME/10% FCS for 48 h and supernatants were collected for cytokine
analysis. (C) Immune deviation with irradiated cells. B6 mice were AC-
injected with TNP-T cells or irradiated (Xrad) TNP-T cells from B6 or
IL-102/2 mice. 48 h later mice were sensitized with 1% TNCB on shaved
abdominal skin. 5 d later mice were challenged with 0.033 ml 10 mM
TNBS in PBS in the right footpad and 0.033 ml PBS in the left footpad.
Measurements (mm 6 SE) were taken 24 h later and represent the differ-
ence between right footpad (antigen challenge) and left footpad (PBS
challenge). Background (Bkg) values represent the difference between
challenged and unchallenged sites in naive mice.892 Apoptosis and Inflammation
Th2 cells is assessed by examining the cytokine profiles of
the resultant cell populations after restimulation with their
specific peptide (OVA323–339; see Materials and Methods).
Adherent PEC were incubated for 2–4 h with irradiated or
untreated T cells from IL-101/1 or IL-102/2 mice before
the addition of purified DO11.10 T cells and OVA. When
IL-4 and IFN-g production were examined in the resultant
cell population (Fig. 5) the presence of irradiated IL-101/1
T cells in the preculture resulted in a Th2-like cytokine
profile (high IL-4, low IFN-g). In contrast, irradiated IL-
102/2 T cells resulted in T cells that were Th1 like (low
IL-4, high IFN-g). Thus, apoptotic cells containing IL-10
were able to influence the differentiation of Th cells.
Discussion
Immune privilege is a multifaceted process that has sig-
nificant biological relevance to organs and tissues key to
survival. An organ’s privilege relates to its ability to control
inflammatory reactions, that can, while attempting to resist
an invader, inflict significant damage to vital structures. No
place is immune privilege better illustrated than in the eye
where numerous mechanisms have been shown to protect
against sight threatening bouts of inflammation (reviewed
in reference 17). Two important components of immune
privilege are the expression of FasL (5) and the develop-
ment of immune deviation (17, 19). FasL controls the
spread of inflammation by killing Fas1 lymphoid cells that
enter the eye, whereas the predisposition to immune devia-
tion after cell death restrains dangerous cell mediated re-
sponses such as DTH in favor of Th2-type reactions. The
mechanisms by which apoptosis and tolerance are linked is
the subject of the present report.
It has been long thought that apoptosis was a passive
process that did not elicit inflammation, but created a sit-
uation where inflammatory responses were not evoked.
However, the well-documented effects of UV irradiation
on the immune response (4), as well as the requirement for
apoptotic cell death to establish an antiinflammatory im-
mune deviation (5), suggest that this may not be the case.
Implicit in these findings is that apoptosis may involve the
induction of antiinflammatory immune responses, thereby
linking cell death and immune tolerance. Our studies re-
ported here found that the production of the antiinflamma-
tory cytokine (IL-10) in the apoptotic cells and targeting of
the apoptotic cells to the APC results in a Th2-type im-
mune deviation. Thus, apoptosis of immune effector cells
(T cells) can redirect the final outcome of an immune re-
sponse to minimize dangerous immune reactions (e.g., Th1
responses) that can damage important organs.
Figure 3. Immune deviation in IL-102/2 and IL-42/2 mice. (A) Immune deviation in IL-102/2
mice. B6 TNP-T cells were AC-injected into B6 (B6 5.B6) or IL-102/2 (B6 5.IL-102/2) mice
48 h before immunization with 1% TNCB on shaved abdominal skin. 5 d later mice were chal-
lenged with 0.033 ml 10 mM TNBS in PBS in the right footpad and 0.033 ml PBS in the left foot-
pad. Measurements (mm 6 SE) were taken 24, 48, and 72 h later and represent the difference be-
tween right footpad (antigen challenge) and left footpad (PBS challenge). Background (Bkg) values
represent the difference between challenged and unchallenged sites in naive mice. (B) Cytokine
production. IL-102/2 mice were injected AC with TNP-T cells from B6 or IL-102/2 mice 48 h
before immunization with 1% TNCB on shaved abdominal skin. 4 d later spleens were harvested,
single-cell suspensions prepared, and cells were coupled with TNP. Cells were then cultured in
DME and 10% FCS for 48 h and supernatants were collected for cytokine analysis. (C) Immune de-
viation in IL-42/2 mice. B6 or IL-42/2 mice were AC-injected with TNP-T cells prepared from
B6 or IL-42/2 mice 48 h before immunization with 1% TNCB on shaved abdominal skin. 5 d later
mice were challenged with 0.033 ml 10 mM TNBS in PBS in the right footpad and 0.033 ml PBS
in the left footpad. Measurements (mm 6 SE) were taken 24 h later and represent the difference be-
tween right footpad (antigen challenge) and left footpad (PBS challenge). Background (Bkg) values
represent the difference between challenged and unchallenged sites in naive mice. Background val-
ues for IL-42/2 mice and B6 mice were essentially identical.893 Gao et al.
To our knowledge, this is the first demonstration of a
link between Fas-mediated death and IL-10 production in
lymphoid effector cells. However, the link between DNA
damage and IL-10 production was recently examined by
Nishigori et al. (32). These authors showed that the pro-
duction of IL-10 was linked to UV-induced pyrimidine
dimers in the keratinocytes of UV-exposed skin. Since IL-
10 is now thought to mediate the well known inhibitory
effects of UV-irradiation on cell mediated immunity (4),
the link to DNA damage suggests a mechanism by which
this takes place. UV-induced apoptosis also requires Fas
(33), supporting our linkage of Fas-mediated death and IL-
10 production. Taken together, these observations show
that apoptosis has an antiinflammatory component that
helps control potentially harmful immune responses.
Our results here also establish that apoptotic cells are tar-
geted to the APC to mediate their effect on cell mediated
immunity. Apoptotic cells are an efficient vehicle to target
the antiinflammatory cytokines to the APC pathways. Ap-
optosis is a natural process resulting in membrane changes
that “mark” the cells for removal by the reticuloendothelial
system. The appearance of phosphatidylserine in the mem-
brane (3) has been shown to be important. Additionally,
phagocytic cells are known to use the avb3integrin/throm-
bospondin receptor (CD36) system to recognize apoptotic
lymphoid cells (34). Although many particles (e.g., protein-
coupled beads) can be phagocytized in vitro (35), apoptotic
cells are much more efficiently taken up in vivo due to
these surface markers (3, 34). This is supported by our re-
cent studies on tolerance induction by intravenous injec-
tion of TNP-T cells. Here we found that irradiation of the
TNP-coupled cells before intravenous injection reduced
the amount of cells needed to achieve tolerance by 200-fold
(17). Thus, apoptosis results in immune deviation and tol-
erance because the antigen-laden cells can be much more
efficiently delivered to the phagocytes. This also provides
another efficient level of control by targeting the regulatory
cytokines where they can most efficiently influence the im-
mune response (i.e., the APC).
A recent scientific correspondence in Nature (36) de-
scribed the production of IL-10 in cultures of monocytes
by exposure to apoptotic PBL. These results support our
conclusions that apoptosis and the production of antiin-
flammatory cytokines are linked. In the experiment shown
in that correspondence, IL-10 was found in cultures where
the monocytes were exposed to UV-irradiated PBL. The
authors concluded that source of the IL-10 was the mono-
cytes stimulated to produce IL-10 by the apoptotic cells, al-
Figure 4. Apoptotic cells and antigen presentation. (A) Adherent PEC
were incubated with live or apoptotic (Xrad) TNP-T cells from B6 mice
for 2 h. (B) The T hybridoma cell A1.1 was activated with PMA and Ion-
omycin before incubation with PEC for 2 h. For A and B, PEC were
then washed, dislodged from the plate, and 1 3 104 viable cells injected
intravenously into naive B6 mice. 48 h later recipient mice were immu-
nized with 1% TNCB on shaved abdominal skin. 5 d later mice were
challenged with 0.033 ml 10 mM TNBS in PBS in the right footpad and
0.033 ml PBS in the left footpad. Measurements (mm 6 SE) were taken
24 h later and represent the difference between right footpad (antigen chal-
lenge) and left footpad (PBS challenge). Background (Bkg) values represent
the difference between challenged and unchallenged sites in naive mice.
Figure 5. Apoptotic cells can direct Th cell development in vitro. Ad-
herent PEC were incubated with live or apoptotic (Xrad) TNP-T cells
from IL-101/1 or IL-102/2 mice for 2–4 h. Recombinant murine IL-10
was included as a control. After washing away the nonassociated cells,
OVA antigen along with purified DO11.10 T cells were added and cul-
tures were maintained for 5 d. Live cells were then harvested and restim-
ulated with OVA323–339 peptide and splenic APC for 48 h. Supernatants
were collected for cytokine analysis.894 Apoptosis and Inflammation
though this was not tested. In light of this, one interpreta-
tion of our results might be that apoptotic T cells induce
monocytes or macrophages to produce IL-10, leading to
the in vivo and in vitro effects in our system. We think this
is unlikely for several reasons. First, apoptotic T cells (5,
15–17, 24) capable of making IL-10 (Fig. 2, A and C) in-
duce immune deviation, whereas apoptotic IL-102/2 T
cells do not. This is further emphasized by our results
showing apoptotic IL-101/1 T cells injected into the AC
induce immune deviation in IL-102/2 mice (Fig. 3 A).
The APC (and any monocytes or macrophages) in this situ-
ation are of recipient origin (i.e., IL-102/2) and can not
synthesize IL-10. The only source of IL-10 is donor T cells
injected into the AC, thus, IL-10 from apoptotic T cells is
responsible. Second, apoptotic IL-101/1 T cells are re-
quired to induce Th2 differentiation of DO11.10 T cells in
culture (Fig. 5), whereas apoptotic IL-102/2 cells promote
Th1 differentiation. Thus, APC in the culture (that are IL-
101/1) can not be stimulated to produce sufficient IL-10 by
the apoptotic T cells to influence T cell differentiation.
Third, a T cell hybridoma induced to undergo AICD pro-
duced significant IL-10, and it activates immune deviation
when presented to the immune system via APC. Thus, al-
though monocytes can produce IL-10, our results show
that the IL-10 is produced by the T cells after the induction
of apoptosis. Taken together, these results are consistent
with our hypothesis that apoptotic T cells make IL-10 and
influence the outcome of the immune response. Although
it is possible that IL-10 production by monocytes may play
a role in regulation of the immune response in other sys-
tems of immune deviation, the apoptotic T cells in the
UV-irradiated PBL, rather than the monocytes, could be
the true source of IL-10 in that system (36).
Although IL-10 has noted properties in the control of
the DTH response (25) and the development of Th2 cells
(22, 23), it also has other important antiinflammatory prop-
erties. IL-10 suppresses the production of proinflammatory
cytokines such as IL-6, TNF-a, and IL-1, and inhibits
chemotaxis by decreasing IL-8 production (37). IL-10 has
also been noted to decrease class II expression (38) and down-
modulate the costimulator B7-1 on macrophages (39).
Thus, the production of IL-10 by apoptotic cells could reg-
ulate several aspects of the inflammatory response to con-
trol potentially damaging reactions. In the present system
IL-10 influences T cell differentiation leading to Th2-type
responses. Although we did not examine mechanisms by
which IL-10 leads to immune deviation, we can speculate
that IL-10 inhibits IL-12 production in the APC (40, 41).
Since IL-12 is critical to the development of Th1 cells (42),
inhibition of this cytokine may lead to Th2 development.
In support of this it has been shown that IL-10 inhibits Th1
activation through the APC (43).
A previous study showed that Th1 and Th2 cells differ-
entially used B7-1 and B7-2 (44). We did not observe any
significant effect on B7 expression after interaction of apop-
totic cells with APC (data not shown), even though IL-10
has been shown to prevent upregulation of B7-1 in mac-
rophages (39). That we observed no significant changes in
B7 expression could be accounted for by noting that these
authors examined the effect of IL-10 on B7 expression dur-
ing PEC activation with IFN-g. We did not investigate the
effect of apoptotic cells on APC activation, but used mac-
rophages that were already activated in vivo. Thus, we
were determining whether IL-10 could decrease or alter
B7-1 and/or B7-2 expression in cells fully capable of in-
ducing differentiation of T cells.
We do not know if the IL-10 is released from the apop-
totic cells when they are brought into close proximity with
the APC or if IL-10 functions after uptake by the phago-
cytes. We have attempted studies with anti-IL-10 antibody
in the preculture but the results are inconclusive due to the
effect of anti–IL-10 on Th cell differentiation in the culture
system (22, 23). We also performed studies using Trans-
wellÔ cultures to determine if contact between the apop-
totic cells and the APC was required for the effect of IL-10
in our system. In this case we saw a partical effect of IL-10
on Th cell differentiation (data not shown), suggesting that
the close proximity of the apoptotic cell is necessary to
concentrate IL-10 to the APC. Since the TranswellÔ was
in place only for 3–4 h, this suggested that sufficient IL-10
was produced in this time period to affect APC function.
We are also examining the interaction of apoptotic cells
with phagocytes to determine the receptors used to take up
the dead cells. We are particularly interested in thrombo-
spondin receptors (CD36) due to their involvement in apop-
totic cell phagocytosis in human systems (34). Unfortu-
nately, the lack of reagents to mouse CD36 has hampered
these studies. However, we do know that apoptotic cells
containing IL-10 are critical for the effect on immune devi-
ation and T cell differentiation since apoptotic IL-102/2
cells do not perform these functions.
The site of interaction of the APC and apoptotic cells in
vivo has not been precisely determined. It is well known
that an intact spleen is required for the establishment of im-
mune deviation when antigens are presented via the eye. It
has been suggested that resident dendritic cells in the eye
capture antigen, enter the blood, and lodge in the spleen.
There they present the antigen to T cells resulting in im-
mune deviation (19). Although it is certainly possible that
apoptotic cells are engulfed by phagocytic cells in the eye,
recent studies in our lab (17) suggest an alternative possibil-
ity. We can detect what appears to be apoptotic bodies in
the blood of animals injected in the eye with TNP cells.
This, coupled with our inability to detect phagocytized ap-
optotic cells in the eye suggest that the dead cells may be
washed from the eye, enter the blood, and interact with the
APC in the spleen. This will require further study.
An interesting result reported here is the ability of
IL-101/1 TNP-T cells injected into the AC to induce im-
mune deviation in IL-102/2 mice. We can infer from this
that IL-10 may not be necessary for the reduction of DTH
responses seen in the periphery of mice with immune devi-
ation. IL-10 has been shown to regulate the magnitude of
the contact hypersensitivity response (25) and is an impor-
tant regulator of IFN-g production (45). However, our re-
sults suggest that reduced IFN-g production in this model895 Gao et al.
may not be mediated directly by IL-10, but may be re-
flected in vivo by a reduction in (or lack of) IFN-g pro-
ducing Th1 cells. Thus, the preferential activation of Th2
cells is the result of altered differentiation rather than a di-
rect regulation of Th1 cells by Th2 cytokines. We also
found that IL-4 was not needed in the eye for immune de-
viation to be established, but was required in the periphery
for Th2 response development. Thus, the increase in Th2
responses requires the presence of IL-4, perhaps as the
growth factor for Th2 cells and a suppressor of Th1 cells.
This has been noted in other models (42, 46) and supports
the idea that the induction of immune deviation in our sys-
tem may be altered differentiation rather direct regulation.
We would suggest that apoptosis and the induction of
antiinflammatory responses may be a more general phe-
nomenon. Killing potentially dangerous cells by apoptosis
and actively regulating inflammation provides an efficient
level of protection in numerous situations. In support of
our hypothesis, Bellone et al. (47) have recently shown that
engulfment and processing of apoptotic bodies can yield
epitopes for cytotoxic T cells. These results, along with
ours, suggest that scavenging of apoptotic cells may have
implications for central and peripheral tolerance. Perhaps
cells other than lymphocytes killed through Fas, with
TNF-a, or through other death receptors use antiinflam-
matory effects and antigen presentation to control inflam-
mation. We would further suggest that the physical associa-
tion of apoptotic cells and self antigens after apoptosis
provides a good way to prevent potential autoimmune
reactions that might ensue during normal physiological re-
sponses. Whether this is a general phenomenon or re-
stricted to immune privileged sites, it is clear that apoptosis
and antiinflammatory immune responses are linked to pro-
vide efficient protection to vital organs critical to survival.
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